Daniel Sokoloff is an associate at Rakoczy Molino Mazzochi Siwik LLP.
LITIGATION
Mr. Sokoloff’s practice focuses on intellectual property litigation, with emphasis on patent infringement suits arising under the Hatch-Waxman Amendments to the Food, Drug and Cosmetic Act and Biologics Price Competition and Innovation Act (BPCIA).
Mr. Sokoloff has experience representing clients in proceedings before the U.S. District Courts, Patent Trial and Appeal Board (“PTAB”), and United States International Trade Commission (“USITC”). He routinely engages in a number of stages of litigation, including pre-suit investigation work and pleadings practice, fact and expert discovery, as well as the pre-trial and trial phases of federal litigation. Additionally, Mr. Sokoloff has represented companies in various other complex matters involving a wide range of telecommunication devices, automotive inventions, and integrated circuit design, with particular involvement in Section 337 proceedings before the USITC.
PRACTICE BEFORE THE U.S. PATENT AND TRADEMARK OFFICE
Mr. Sokoloff is registered to practice before the United States Patent and Trademark Office and has experience with post grant proceedings before the PTAB.
PREVIOUS EXPERIENCE
Prior to joining Rakoczy Molino Mazzochi Siwik LLP as an associate, Mr. Sokoloff was an associate at Irwin IP, LLC, Kheyfits Belenky, LLP, and Erise IP, PA. Before attending law school, Mr. Sokoloff worked as an intellectual property paralegal specializing in USITC matters.
Mr. Sokoloff is registered to practice before the United States Patent and Trademark Office and has experience with post grant proceedings before the PTAB.
Education
Washington University in St. Louis School of Law
(J.D.)
Johns Hopkins University
(B.A., Biology)
Bar Admissions
Illinois
Texas
Kansas
United States Patent & Trademark Office
Court Admissions
N.D. Illinois
Kansas
Organizations
Abhilash Guduru, Jason Lansdown, “Daniel Sokoloff,” Ronald D. Berger & Larisa G. Tereshchenko, Longitudinal Changes in Intracardiac Repolarization Lability in Patients with Implantable Cardioverter-defibrillator, 4 Front. Physiol., Art. 208 (August, 2013).